JP2013528607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528607A5 JP2013528607A5 JP2013511702A JP2013511702A JP2013528607A5 JP 2013528607 A5 JP2013528607 A5 JP 2013528607A5 JP 2013511702 A JP2013511702 A JP 2013511702A JP 2013511702 A JP2013511702 A JP 2013511702A JP 2013528607 A5 JP2013528607 A5 JP 2013528607A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody according
- antibody
- disease
- conservative
- forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030533 eye disease Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000009043 Chemical Burns Diseases 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 206010061788 Corneal infection Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 241001071795 Gentiana Species 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002497 edematous effect Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34927110P | 2010-05-28 | 2010-05-28 | |
| US61/349,271 | 2010-05-28 | ||
| PCT/EP2011/058777 WO2011147984A1 (en) | 2010-05-28 | 2011-05-27 | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528607A JP2013528607A (ja) | 2013-07-11 |
| JP2013528607A5 true JP2013528607A5 (enExample) | 2014-06-26 |
| JP5990511B2 JP5990511B2 (ja) | 2016-09-14 |
Family
ID=44276158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511702A Expired - Fee Related JP5990511B2 (ja) | 2010-05-28 | 2011-05-27 | 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9045544B2 (enExample) |
| EP (1) | EP2575881B1 (enExample) |
| JP (1) | JP5990511B2 (enExample) |
| KR (1) | KR101847572B1 (enExample) |
| CN (2) | CN107648605A (enExample) |
| BR (1) | BR112012030318A2 (enExample) |
| CA (1) | CA2796312C (enExample) |
| DK (1) | DK2575881T3 (enExample) |
| ES (1) | ES2606627T3 (enExample) |
| PL (1) | PL2575881T3 (enExample) |
| WO (1) | WO2011147984A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561707B2 (en) * | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| US20170056469A1 (en) * | 2014-05-02 | 2017-03-02 | Mayo Foundation For Medical Education And Research | Individualized treatment of eye disease |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| CN110121508A (zh) * | 2016-10-25 | 2019-08-13 | 法国国家健康和医学研究院 | 与cd160跨膜同种型结合的单克隆抗体 |
| FR3061716B1 (fr) | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
| AU2018326835A1 (en) * | 2017-08-31 | 2020-03-26 | National University Of Singapore | Angio-3 for treatment of retinal angiogenic diseases |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230073132A1 (en) * | 2019-12-31 | 2023-03-09 | Medstar Health, Inc. | Anti-cd 160 binding molecules for treating diseases |
| WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
| IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Double structure antibodies |
| IL319570A (en) | 2022-09-15 | 2025-05-01 | Avidicure Ip B V | Multispecific antigen-binding proteins for targeting NK cells to tumors and their uses |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| WO1994013806A1 (en) | 1992-12-11 | 1994-06-23 | The Dow Chemical Company | Multivalent single chain antibodies |
| WO1998021240A1 (en) | 1996-11-12 | 1998-05-22 | Dana-Farber Cancer Institute | Recombinant by55 and nucleic acids encoding same |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| FR2794977B1 (fr) * | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| EP1626059A1 (en) * | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| EP1981520A2 (en) * | 2006-01-30 | 2008-10-22 | (OSI) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
| AR062239A1 (es) | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
-
2011
- 2011-05-27 EP EP11728594.0A patent/EP2575881B1/en active Active
- 2011-05-27 CA CA2796312A patent/CA2796312C/en active Active
- 2011-05-27 CN CN201710912201.2A patent/CN107648605A/zh active Pending
- 2011-05-27 JP JP2013511702A patent/JP5990511B2/ja not_active Expired - Fee Related
- 2011-05-27 US US13/697,699 patent/US9045544B2/en active Active
- 2011-05-27 WO PCT/EP2011/058777 patent/WO2011147984A1/en not_active Ceased
- 2011-05-27 PL PL11728594T patent/PL2575881T3/pl unknown
- 2011-05-27 CN CN201180024138XA patent/CN102892432A/zh active Pending
- 2011-05-27 KR KR1020127034345A patent/KR101847572B1/ko not_active Expired - Fee Related
- 2011-05-27 BR BR112012030318A patent/BR112012030318A2/pt not_active Application Discontinuation
- 2011-05-27 DK DK11728594.0T patent/DK2575881T3/en active
- 2011-05-27 ES ES11728594.0T patent/ES2606627T3/es active Active
-
2015
- 2015-06-02 US US14/728,253 patent/US10208124B2/en active Active